Based on 15 Wall Street analysts offering 12 month price targets for Fate Therapeutics in the last 3 months. The average price target is $7.27 with a high forecast of $11.00 and a low forecast of $5.00. The average price target represents a 44.25% change from the last price of $5.04.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","3":"$3","6":"$6","9":"$9","12":"$12"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$11.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$7.27</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3,6,9,12],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2023","6":"Oct<br/>2023","9":"Jan<br/>2024","12":"Apr<br/>2024","25":"Apr<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.92,7.233846153846153,7.547692307692308,7.861538461538461,8.175384615384615,8.489230769230769,8.803076923076922,9.116923076923076,9.430769230769231,9.744615384615384,10.058461538461538,10.372307692307693,10.686153846153847,{"y":11,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.92,6.946923076923077,6.973846153846154,7.00076923076923,7.027692307692307,7.054615384615384,7.081538461538461,7.108461538461539,7.135384615384615,7.162307692307692,7.189230769230769,7.216153846153846,7.243076923076923,{"y":7.27,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.92,6.772307692307693,6.624615384615384,6.476923076923077,6.329230769230769,6.181538461538461,6.033846153846154,5.886153846153846,5.7384615384615385,5.590769230769231,5.443076923076923,5.295384615384616,5.147692307692308,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.01,"date":1681430400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.68,"date":1683244800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.25,"date":1685664000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.77,"date":1688688000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.73,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.81,"date":1693526400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.78,"date":1696550400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.39,"date":1698969600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.65,"date":1701388800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.77,"date":1704412800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6.52,"date":1706832000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":7.74,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.92,"date":1712275200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$11.00

Average Price Target$7.27

Lowest Price Target$5.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

xxxxxxxxxxxxxxxxxx

Needham

xxxxxxxxxxxxx

Reiterated

04/11/24

xxxxxxxxxxxxxxxxxx

Bank of America Securities

xxxxxxxxxxxxx

Reiterated

03/28/24

xxxxxxxxxxxxxxxxxx

Barclays

xxxxxxxxxxxxx

Reiterated

03/25/24

xxxxxxxxxxxxxxxxxx

H.C. Wainwright

xxxxxxxxxxxxx

Reiterated

03/19/24

xxxxxxxxxxxxxxxxxx

Stifel Nicolaus

xxxxxxxxxxxxx

Reiterated

02/28/24

xxxxxxxxxxxxxxxxxx

Leerink Partners

xxxxxxxxxxxxx

Reiterated

02/28/24

xxxxxxxxxxxxxxxxxx

Canaccord Genuity

xxxxxxxxxxxxx

Reiterated

02/27/24

xxxxxxxxxxxxxxxxxx

Wedbush

xxxxxxxxxxxxx

Reiterated

02/27/24

xxxxxxxxxxxxxxxxxx

TD Cowen

xxxxxxxxxxxxx

Assigned

02/27/24

xxxxxxxxxxxxxxxxxx

Morgan Stanley

xxxxxxxxxxxxx

Reiterated

02/27/24

Matthew Biegler

Oppenheimer

―

Hold

―

Reiterated

02/27/24

Oppenheimer Reaffirms Their Hold Rating on Fate Therapeutics (FATE)

Jack Allen

Robert W. Baird

$5.00

Hold

-0.79%

Downside

Reiterated

02/27/24

Fate Therapeutics: Hold Rating Maintained Amid Anticipation of Pivotal Clinical Data

Etzer Darout

BMO Capital

$7.00

Hold

38.89%

Upside

Reiterated

02/26/24

Market Perform: A Cautious Outlook on Fate Therapeutics' Clinical Progress and Immunology Prospects

Yanan Zhu

Wells Fargo

$5.00

Hold

-0.79%

Downside

Reiterated

02/26/24

Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (NASDAQ: FATE), BioCryst (NASDAQ: BCRX) and Veeva Systems (NYSE: VEEV)

Salim Syed

Mizuho Securities

$8.00

Buy

58.73%

Upside

Initiated

02/09/24

Best Analysts Covering Fate Therapeutics

Which Analyst Should I Follow If I Want to Buy FATE and Sell After:

1 Month

Peter LawsonBarclays

Success Rate

4/10 ratings generated profit

Average Return

+4.11%

reiterated a buy rating 26 days ago

Copying Peter Lawson's trades and holding each position for 1 Month would result in 40.00% of your transactions generating a profit, with an average return of +4.11% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

3 Months

Daina GrayboschLeerink Partners

Success Rate

10/23 ratings generated profit

Average Return

+3.50%

reiterated a buy rating 2 months ago

Copying Daina Graybosch's trades and holding each position for 3 Months would result in 43.48% of your transactions generating a profit, with an average return of +3.50% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

1 Year

Peter LawsonBarclays

Success Rate

4/10 ratings generated profit

Average Return

+9.66%

reiterated a buy rating 26 days ago

Copying Peter Lawson's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of +9.66% per trade.

2 Years

Peter LawsonBarclays

Success Rate

3/10 ratings generated profit

Average Return

-26.07%

reiterated a buy rating 26 days ago

Copying Peter Lawson's trades and holding each position for 2 Years would result in 30.00% of your transactions generating a profit, with an average return of -26.07% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

FATE Analyst Recommendation Trends

Rating

Nov 23

Jan 24

Feb 24

Mar 24

Apr 24

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, FATE has received 5 Buy Ratings, 11 Hold Ratings, and 1 Sell Ratings. FATE average Analyst price target in the past 3 months is $7.27.

Each month's total comprises the sum of three months' worth of ratings.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxxxxxxxxxxxxxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

FATE Financial Forecast

FATE Earnings Forecast

Next quarter’s earnings estimate for FATE is -$0.48 with a range of -$0.57 to -$0.37. The previous quarter’s EPS was -$0.45. FATE beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.49% of the time in the same period. In the last calendar year FATE has Outperformed its overall industry.

FATE Sales Forecast

Next quarter’s sales forecast for FATE is $1.66M with a range of $0.00 to $8.00M. The previous quarter’s sales results were $1.68M. FATE beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.20% of the time in the same period. In the last calendar year FATE has Outperformed its overall industry.

FATE Stock Forecast FAQ

What is FATE’s average 12-month price target, according to analysts?

Based on analyst ratings, Fate Therapeutics’s 12-month average price target is $7.27.

What is FATE’s upside potential, based on the analysts’ average price target?

Fate Therapeutics has 44.25% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is FATE a Buy, Sell or Hold?

Fate Therapeutics has a conensus rating of Hold which is based on 4 buy ratings, 10 hold ratings and 1 sell ratings.

What is Fate Therapeutics’s price target?

The average price target for Fate Therapeutics is $7.27. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $11.00 ,the lowest forecast is $5.00. The average price target represents 44.25% Increase from the current price of $5.04.

What do analysts say about Fate Therapeutics?

Fate Therapeutics’s analyst rating consensus is a Hold. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of FATE?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Fate Therapeutics (FATE) Stock Forecast & Price Target

FATE Analyst Ratings

FATE Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Fate Therapeutics

FATE Analyst Recommendation Trends

FATE Financial Forecast

FATE Earnings Forecast

FATE Sales Forecast

FATE Stock Forecast FAQ

Get More with TipRanks Premium

Detailed List of Analyst Forecasts